A pt-141 dosage chart for women begins with the FDA-approved 1.75 mg injection, plus what research says about nasal spray and compounded dosing.
There is no official PT-141 dosage chart for women beyond the FDA-approved label. Bremelanotide, marketed as Vyleesi, is approved for premenopausal women with hypoactive sexual desire disorder (HSDD) at one fixed dose: 1.75 mg injected subcutaneously at least 45 minutes before anticipated sexual activity. That dose is capped at one injection per 24 hours and no more than eight injections per month.
Any chart showing different numbers — tapering schedules, "loading" doses, spray counts, or weight-based calculations — comes from compounded products, clinic protocols, or research studies rather than approved labeling. That is the most important thing to understand before you compare charts.
What the Approved PT-141 Dose for Women Looks Like
Vyleesi is a single-use autoinjector that delivers 1.75 mg of bremelanotide. The label is rigid because PT-141 works through melanocortin receptors, and higher exposure has not been shown to improve response in women while it does increase nausea.
- Dose: 1.75 mg given subcutaneously.
- Timing: at least 45 minutes before anticipated sexual activity.
- Maximum frequency: one dose per 24 hours; no more than eight doses per month.
- Injection site: abdomen or thigh, rotating sites to limit irritation.
The most reliable pt-141 dosage for women is the one printed on that label. Charts that push the dose higher are describing off-label or compounded use, which carries different risks and no standardized product behind it.
Why Online PT-141 Dosage Charts for Women Disagree
Most charts circulating online are built around compounded bremelanotide or research protocols, not approved products. Compounded vials vary in concentration, so "10 units" from one pharmacy is not the same amount of drug as "10 units" from another.
Clinical research adds a second layer of confusion. Early bremelanotide trials tested several dose levels under monitored conditions, and those numbers get copied into consumer-facing charts without the study context that made them safe to test. A dose that appears in a trial safety cohort is not automatically a dose to self-administer.
Vendors selling "research only" peptides typically publish no validated dosing information at all, and the purity and identity of those products is unverified. Charts attributed to them are marketing, not pharmacology.
Injection vs. Nasal Spray vs. Compounded Options
| Route | Dose commonly listed in charts | FDA-approved for women? | Key caveat |
|---|---|---|---|
| Subcutaneous autoinjector (Vyleesi) | 1.75 mg, once per 24 hours, max 8 per month | Yes | Fixed dose; no titration needed |
| Compounded subcutaneous injection | Varies by clinic; often listed below and above 1.75 mg | No | Concentration and sterility depend on the pharmacy |
| Compounded nasal spray | Listed inconsistently, often as "sprays per session" | No | Absorption is uneven; the pt-141 nasal spray dosage for women is not standardized |
| Sublingual or topical | Anecdotal reports only | No | Almost no pharmacokinetic data in women |
Early nasal research on bremelanotide used substantially larger milligram amounts than the injected product, which is one reason nasal charts copied from those studies describe doses that look nothing like 1.75 mg. Nasal absorption also varies with technique, congestion, and formulation.
Can a PT-141 Dosage Calculator Help?
Many people look for a pt-141 dosage calculator for women, but most calculators do one narrow job: they convert a vial concentration in mg/mL into syringe units. They cannot tell you whether the underlying dose is appropriate, evidence-based, or safe for your health history.
Use a calculator only to double-check arithmetic after a prescriber has already set the dose. Never use one to reverse-engineer a dose from a chart you found online.
Side Effects and Safety Considerations
Nausea is the most commonly reported side effect of bremelanotide in women, occurring in roughly 40% of participants in the clinical trials that supported approval. Flushing, headache, injection-site reactions, vomiting, and fatigue are also common, and nausea tends to lessen with continued use.
People researching pt-141 dosage for women side effects should also know about two less obvious issues:
- Blood pressure: PT-141 can cause a temporary rise in blood pressure. It is contraindicated in women with uncontrolled hypertension or known cardiovascular disease.
- Hyperpigmentation: Darkening of the gums, face, or other skin areas has been reported with frequent or daily dosing, and it may not fully reverse after stopping.
Bremelanotide is not recommended during pregnancy, and it is not known whether it passes into breast milk. Anyone with a history of heart disease, stroke, or uncontrolled blood pressure should not use it without explicit medical clearance.
How PT-141 Dosing Compares for Men
Bremelanotide is not FDA-approved for men, and no male version of Vyleesi is marketed in the United States. Studies in men with erectile dysfunction tested subcutaneous doses around 1.25 mg to 1.75 mg and found modest effects, which is why pt-141 peptide dosage for men also comes from unofficial sources and trial data rather than an approved label.
Doses are not simply transferable between sexes. Body composition, side-effect tolerance, and the condition being treated all differ, so a male-oriented chart is not a shortcut for women.
Before You Follow Any Chart
- Confirm what you have: an FDA-approved autoinjector is not interchangeable with a compounded vial or a spray.
- Get a prescription and a baseline blood pressure reading from a clinician.
- Start at the approved 1.75 mg dose if you are using Vyleesi, and do not stack extra doses in one day.
- Log each dose, the timing, and any side effects so you and your clinician can judge whether it is working.
- Stop and seek care for chest pain, severe headache, or a sudden rise in blood pressure.
PT-141 is a prescription medication with real cardiovascular and tolerability considerations, and the approved product is not inexpensive or universally covered by insurance. A candid conversation with a healthcare professional about goals, expectations, and alternatives is worth more than any chart on the internet.
Frequently Asked Questions
What is the normal PT-141 dosage for women?
The only FDA-approved dose for women is 1.75 mg injected subcutaneously with the Vyleesi autoinjector, given at least 45 minutes before anticipated sexual activity. It is limited to one dose per 24 hours and no more than eight doses per month. Compounded injections and nasal sprays are not FDA-approved and their doses vary by pharmacy.
Is there an approved PT-141 nasal spray dose for women?
No nasal bremelanotide product is FDA-approved, so there is no official nasal dose for women. Early nasal research used much larger milligram amounts than the injected product, and compounded sprays are unstandardized with inconsistent absorption. Anyone considering a spray should discuss it with a clinician rather than follow an online chart.
What are the most common PT-141 side effects in women?
Nausea is the most frequently reported side effect, affecting roughly 40% of women in the trials that supported approval, along with flushing, headache, injection-site reactions, and fatigue. PT-141 can also raise blood pressure temporarily and has been linked to skin darkening with frequent dosing. It is contraindicated in women with uncontrolled hypertension or known cardiovascular disease.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.